Stock listing

NASDAQ:XLO Xilio Therapeutics, Inc. Stock

Home listing (NASDAQ) of Xilio Therapeutics, Inc.

Follow Xilio Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:XLO

$7.56 USD -0.07 (-0.9%)

Close on Nov 20, 2026

Past year -28.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.07 – $7.60 USDNov 20, 2026
Volume
20,100 sharesNov 20, 2026
Market cap
$53.40M USDAt the close on Nov 20, 2026 · price × 7.06M shares outstanding
52-week range
$6.47 – $10.71 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$98,525 USDMedian day 9,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Xilio Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:XLO · Home$7.56 USD-0.07 (-0.9%)20,100$7.60$7.60$7.065$7.63Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XLO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.56-0.07-0.9%$7.60$7.60$7.06520,100
$7.63+0.09+1.2%$7.879$7.94$7.258,083
$7.54-0.16-2.1%$7.805$7.837$7.146,147
$7.70-0.375-4.6%$7.87$8.44$7.108,377
$8.075-0.165-2.0%$7.96$8.075$7.857,515
$8.24-0.23-2.7%$8.25$8.25$7.969,084
$8.47-0.06-0.7%$8.82$8.82$8.4053,528
$8.53-0.47-5.2%$8.53$8.53$8.533,078
$9.00+0.38+4.4%$8.857$9.00$8.5710,623
$8.62+0.12+1.4%$8.24$8.69$8.246,639
$8.50-0.21-2.4%$8.45$8.65$7.77526,839
$8.71+0.03+0.3%$8.425$8.86$8.42511,854
$8.68+0.69+8.6%$8.03$8.85$7.93524,451
$7.99-0.04-0.5%$7.49$8.065$7.496,802
$8.03+0.26+3.3%$7.05$8.089$7.057,720
$7.77-0.24-3.0%$7.93$7.93$7.772,588
$8.010.000.0%$7.81$8.19$7.5716,674
$8.01+0.70+9.6%$7.855$8.01$7.1727,920
$7.31-0.26-3.4%$7.54$8.637$7.0533,066
$7.57-0.46-5.7%$8.06$8.245$7.5116,300
$8.03-0.40-4.7%$8.45$8.48$8.0015,400
$8.43-0.11-1.3%$8.545$9.05$8.24936,300
$8.54+0.21+2.5%$8.25$8.84$8.2513,500
$8.33-0.22-2.6%$8.69$8.735$8.3311,500
$8.55-0.47-5.2%$8.91$9.00$8.5529,600
$9.02+0.12+1.3%$8.88$9.38$8.8810,400
$8.90-0.32-3.5%$9.08$9.08$8.77212,400
$9.22+0.145+1.6%$9.05$9.22$8.85518,100
$9.075+0.025+0.3%$9.11$9.42$8.9828,400
$9.05+0.04+0.4%$8.94$9.16$8.825,500
$9.010.000.0%$9.01$9.14$8.77520,800
$9.01+0.01+0.1%$9.00$9.01$9.00900
$9.00-0.11-1.2%$9.10$9.32$8.816,200
$9.11+0.10+1.1%$9.07$9.49$9.077,200
$9.01+0.10+1.1%$8.89$9.075$8.897,400
$8.91-0.14-1.5%$8.97$9.12$8.7912,900
$9.05+0.112+1.3%$9.19$9.25$9.055,400
$8.938-0.112-1.2%$9.568$9.568$8.9383,100
$9.05+0.01+0.1%$9.21$9.22$8.9611,100
$9.04+0.04+0.4%$9.00$9.21$8.933,400
$9.00+0.06+0.7%$8.93$9.09$8.9316,000
$8.94-0.10-1.1%$9.03$9.04$8.941,300
$9.04+0.02+0.2%$9.04$9.16$8.956,900
$9.02-0.11-1.2%$8.96$9.175$8.967,100
$9.13+0.09+1.0%$8.995$9.67$8.9422,900
$9.04+0.06+0.7%$9.00$9.049$8.9314,500
$8.98-0.05-0.6%$9.02$9.02$8.9311,500
$9.03+0.10+1.1%$8.93$9.03$8.9317,300
$8.930.000.0%$9.06$9.21$8.9310,300
$8.930.000.0%$8.93$9.49$8.935,100
$8.93-0.04-0.4%$8.95$9.00$8.9311,800
$8.97+0.06+0.7%$8.91$9.00$8.809,000
$8.91-0.09-1.0%$9.03$9.11$8.8110,000
$9.00-0.02-0.2%$9.231$9.231$8.817,600
$9.02+0.18+2.0%$8.94$9.10$8.7216,600
$8.84-0.04-0.5%$9.142$9.142$8.844,700
$8.88-0.07-0.8%$8.57$9.248$8.5731,100
$8.95-0.05-0.6%$9.00$9.27$8.9014,600
$9.00-0.01-0.1%$8.995$9.28$8.9953,600
$9.01-0.04-0.4%$8.785$9.115$8.7859,000
$9.05-0.03-0.3%$9.09$9.145$8.9227,700
$9.08-0.11-1.2%$9.16$9.30$9.085,895
$9.19-0.04-0.4%$9.32$9.32$9.172,293
$9.230.000.0%$9.21$9.23$9.075,200
$9.23-0.18-1.9%$9.27$9.27$9.116,400

Splits

1 split · NASDAQ:XLO · every price before a split is adjusted for it

DayRatioWhat
1-for-14Consolidation
Ticker
NASDAQ:XLO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Xilio Therapeutics, Inc. news

Xilio Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 71 in all · newest Nov 10, 2026 · oldest 2021
Decks
11 decks · latest Mar 9, 2026

Where Xilio Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:XLO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:XLOBOATSUnited StatesUSD

Valuation

EV/sales −1.1× against a median of 248×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$62.82M USD
P/E
Loss
EV/sales
−1.1×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
99.4%
Operating margin
−74.9%
Net margin
−20.9%
Debt to equity
0.1×
Beta vs S&P 500
0.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Xilio Therapeutics, Inc. · NASDAQ:XLOUS$53.40M−US$62.82Mn/a−1.1×n/a0.8×−20.9%0.1×0.76
Cognition Therapeutics, Inc. · NASDAQ:CGTXUS$55.37MUS$25.10Mn/an/an/a1.9×n/a0.0×2.28
AB Science SA · EURONEXT:ABUS$55.19MUS$50.54Mn/a39.2×n/an/a−132.6%n/an/a
Azora Therapeutics, Inc. · NASDAQ:AZRUS$55.00MUS$33.00Mn/an/an/an/an/an/a1.00
Island Pharmaceuticals Ltd · ASX:ILAUS$54.84MUS$46.32Mn/a248×n/a6.2×n/a0.0×n/a
Anavex Life Sciences Corp. · NASDAQ:AVXLUS$54.83M−US$63.50Mn/an/an/a0.5×n/a0.0×2.39
Nordicus Partners Corp · OTC:NORDUS$54.44MUS$54.44Mn/an/an/a0.9×n/a0.0×0.45
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
Median of the othersUS$54.64MUS$39.66M33.0×248×0.9×−132.6%0.0×0.65

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
18.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.95 · 1 analyst
Revenue, year to Dec 2026
45.32M · 1 analyst

Team and board

Officers

OfficerRole
René RussoPresident and Chief Executive Officer
Chris FrankenfieldChief Financial and Operating Officer
Ben HarshbargerChief Legal Officer
Nathan McBrideChief Information Officer
Scott ColemanChief Development Officer
Uli BialuchaChief Scientific Officer
Yariv HouvrasChief Medical Officer

Board

DirectorRole
Sara BonsteinChair of the Board
Akintunde BelloBoard Member
Aoife BrennanBoard Member
Cheryl R. BlanchardBoard Member
Daniel CurranBoard Member
James ShannonBoard Member
René RussoPresident and Chief Executive Officer
Robert RossBoard Member
Yuan XuBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−5.2%
Q2 2026Aug 12, 2026 · Before open−1.4%
Q1 2026May 12, 2026+0.4%
Q4 2025Mar 4, 2026+2.5%
Q3 2025Nov 13, 2025 · Before open−9.2%
Q2 2025Aug 14, 2025 · Before open−1.7%
Q1 2025May 8, 2025 · Before open+8.0%
Q4 2024Mar 11, 2025−2.4%
Q3 2024Nov 7, 2024 · Before open−19.4%
Q2 2024Aug 8, 2024 · Before open−0.3%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 1, 2024 · After close−3.3%
Q4 2023Feb 7, 2024 · After close−8.5%
Q3 2023Nov 9, 2023 · After close−10.6%
Q2 2023Aug 14, 2023 · Before open+2.1%
Q1 2023May 9, 2023 · Before open+2.1%
Q4 2022Mar 2, 2023 · After close+2.9%
Q3 2022Nov 9, 2022 · Before open−1.0%
Q2 2022Aug 9, 2022 · Before open−26.2%
Q1 2022May 12, 2022 · Before open−2.6%
Q4 2021Mar 1, 2022 · Before open−7.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck36 slidesMar 9, 2026
Investor Presentation (June 2025)Investor deck44 slidesJun 2, 2025
Investor Presentation (January 2025)Investor deck43 slidesJan 21, 2025
Investor Presentation (December 2024)Investor deck42 slidesDec 19, 2024
Q3 2024 Earnings PresentationEarnings50 slidesNov 7, 2024
Q2 2023 Earnings PresentationEarnings52 slidesAug 14, 2023
Corporate Update (May 2023)Corporate update54 slidesMay 25, 2023
Investor Presentation (January 2023)Investor deck39 slidesJan 9, 2023
Q3 2022 Earnings PresentationEarnings37 slidesNov 9, 2022
Q1 2022 Earnings PresentationEarnings34 slidesMay 12, 2022
All 11 decks
DeckKindSlidesDate
2021 Next-Gen Cytokines SummitConference27 slidesSep 22, 2021

Open Decks

Financings

RaiseDate
Public offering of pre-funded warrants
Announced: about US$40M · US$0.5349 a share · Warrants at US$0.0001 · Leerink Partners
Dealers: Leerink Partners (lead)
Buyers: Coastlands Capital (led the financing; existing investor); Gilead Sciences, Inc.; OrbiMed; Perceptive Advisors
Use of proceeds: Advance development of product candidates, working capital and general corporate purposes
Feb 12, 2026
Public offering of pre-funded warrants accompanied by Series A, Series B and Series C warrants
Closed: US$50M raised · US$0.7499 a share · Warrants at US$0.75 · Leerink Partners
Dealers: Leerink Partners (lead)
Buyers: Coastlands Capital; Frazier Life Sciences; Gilead Sciences, Inc.; Logos Capital; Samsara BioCapital
Use of proceeds: Advance development of product candidates, working capital and general corporate purposes
Jun 5, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Oct 21, 2021.

Price
US$16.00 a share
Shares offered
7,353,000 shares of common stock
Offering size
US$117.6 million
Underwriters' option
Up to 1,102,950 more shares
Listing
XLO on the Nasdaq Global Select Market
Underwriters
MORGAN STANLEY, COWEN, GUGGENHEIM SECURITIES, RAYMOND JAMES · In the order on the cover
Shares delivered
On or about Oct 26, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 24, 2021
Filed publiclyOct 1, 2021
Amended twiceNewest Oct 20, 2021
Shares registered with an exchangeOct 18, 2021
Declared effective by the SECOct 21, 2021
Final prospectus, with the priceOct 22, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Oct 22, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue43.8M6.34M00000
Cost of revenue1.54M1.64M1.90M1.85M1.50M1.06M240.0K
Gross profit42.2M6.34M-1.90M-1.85M-1.50M-1.06M-240.0K
Research and development56.0M41.2M52.1M59.2M51.2M43.9M14.3M
Selling, general and administrative29.7M24.8M27.0M29.9M23.9M10.7M4.77M
Operating income-42.0M-60.6M-79.1M-89.1M-75.0M-54.6M-19.0M
Depreciation and amortization1.54M1.64M1.90M1.85M1.50M1.06M240.0K
EBITDA-40.4M-58.9M-77.2M-87.3M-73.5M-53.5M-18.8M
Interest expense100.0K127.8K927.0K756.0K600.0K0
Income before tax-35.0M-58.2M-76.4M-88.2M-75.8M-55.2M-17.3M
Income tax00000068.1K
Net income-35.0M-58.2M-76.4M-88.2M-75.8M-55.2M-17.3M
Earnings per share, basic-4.19-15.24-2.78-3.22-13.52-105.42-592.11
Earnings per share, diluted-4.19-15.24-2.78-3.22-13.52-105.42

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents137.5M55.3M44.7M120.4M198.1M19.2M48.8M
Receivables5.00M267.0K393.0K
Current assets145.0M60.2M48.1M124.5M202.5M20.6M51.1M
Property, plant and equipment3.89M4.47M5.94M7.25M7.62M7.37M9.87M
Total assets154.7M71.1M60.9M139.2M218.1M36.3M62.7M
Accounts payable3.17M2.57M1.05M3.13M3.14M5.44M2.52M
Current liabilities56.3M27.3M16.0M21.1M12.8M22.2M5.21M
Long-term debt3.17M9.63M7.41M9.61M
Total debt6.95M8.14M12.5M19.9M20.7M21.9M18.6M
Total liabilities119.4M53.5M24.1M33.5M32.6M41.6M24.2M
Shareholders' equity35.3M17.6M36.8M105.6M185.4M-83.3M38.5M
Shares outstanding4.53M3.27M27.6M27.4M27.4M689.9K29.2K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-4.99M-18.4M-68.6M-75.7M-80.8M-36.1M-17.8M
Capital spending-518.0K-36.0K-486.0K-1.87M-1.10M-2.19M-715.0K
Free cash flow-5.51M-18.4M-69.1M-77.6M-81.9M-38.3M-18.6M
Cash from investing-518.0K-36.0K-486.0K-1.87M-1.10M-2.19M-715.0K
Cash from financing87.8M29.2M-6.55M-69.0K260.7M10.0M60.0M
Share buybacks2.81M194.0K16.0K261.5M
Change in cash82.3M10.8M-75.7M-77.7M178.8M-28.3M41.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 10, 2026Offer documentSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansAug 12, 2026Offer documentSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveJun 1, 2026Other filingsSEC
CORRESP · Letter to the SECMay 27, 2026Other filingsSEC
S-3/A · Registration statement, amendedMay 27, 2026Offer documentSEC
UPLOAD · Letter from the SECMay 18, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
S-3 · Registration statementMay 12, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportApr 16, 2026Management or board changeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 23, 2026ResultsSEC
8-K · Current reportMar 12, 2026Current reportSEC
8-K · Current reportMar 9, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Meeting outcomeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 12, 2026Material contractSEC
424B5 · ProspectusFeb 12, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
424B5 · ProspectusFeb 11, 2026Offer documentSEC
DEF 14A · Proxy statementJan 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJan 16, 2026Meeting noticeSEC
8-K · Current reportJan 8, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 11, 2025Big-stake noticeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
S-8 · Registration statement for employee plansNov 25, 2025Offer documentSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
8-K · Current reportNov 25, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 7, 2025Current reportSEC
DEF 14A · Proxy statementOct 20, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 10, 2025Meeting noticeSEC
8-K · Current reportOct 3, 2025Current reportSEC
8-K · Current reportSep 9, 2025Current reportSEC
8-K · Current reportAug 28, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 18, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 12, 2025Big-stake noticeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
8-K · Current reportJun 10, 2025Management or board changeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
DEFA14A · Additional proxy materialJun 3, 2025Meeting noticeSEC
8-K · Current reportJun 3, 2025Material contractSEC
424B5 · ProspectusJun 3, 2025Offer documentSEC
424B5 · ProspectusJun 2, 2025Offer documentSEC
8-K · Current reportJun 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 9, 2025Other filingsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
CORRESP · Letter to the SECMay 6, 2025Other filingsSEC
S-3/A · Registration statement, amendedMay 6, 2025Offer documentSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
8-K · Current reportApr 8, 2025Current reportSEC
UPLOAD · Letter from the SECMar 17, 2025Other filingsSEC
S-3 · Registration statementMar 11, 2025Offer documentSEC
8-K · Current reportMar 11, 2025Material contractSEC
424B5 · ProspectusMar 11, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
8-K · Current reportFeb 12, 2025Material contractSEC
8-K · Current reportJan 21, 2025Current reportSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 19, 2024Big-stake noticeSEC
8-K · Current reportDec 19, 2024FinancingSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
SC 13G · Big-stake noticeSep 27, 2024Big-stake noticeSEC
3 · Initial statement of ownershipSep 27, 2024Insider tradeSEC
8-K · Current reportSep 13, 2024Current reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 31, 2024Big-stake noticeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
8-K · Current reportJun 13, 2024Management or board changeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 7, 2024Other filingsSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
CORRESP · Letter to the SECMay 2, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 2, 2024Other filingsSEC
S-3 · Registration statementApr 30, 2024Offer documentSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
424B5 · ProspectusApr 15, 2024Offer documentSEC
SC 13G · Big-stake noticeApr 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedApr 5, 2024Big-stake noticeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2024Insider tradeSEC
S-8 · Registration statement for employee plansApr 1, 2024Offer documentSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
8-K · Current reportApr 1, 2024ResultsSEC
8-K · Current reportMar 28, 2024Current reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2024Big-stake noticeSEC
8-K · Current reportJan 19, 2024Current reportSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
8-K · Current reportJan 3, 2024Management or board changeSEC
8-K · Current reportDec 7, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q/A · Quarterly report, amendedNov 9, 2023Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 9, 2023Quarterly reportSEC

This page holds 200 of 364 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Xilio Therapeutics, Inc.’s releases · as of Nov 6, 2026

Common shares
7,063,982
Fully diluted
7,063,982

Fully diluted

LineSharesAs of
Common shares7,063,982Nov 6, 2026

Warrants and options

Lot
Warrants · US$0.75 · expiry not stated

Share count over time

CountShares
Nov 6, 20267,063,982

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Bain Capital Life Sciences Investors, LLC664K9.4%US$6.01MSep 30, 2026
Orbimed Advisors LLC592K8.4%US$5.36MSep 30, 2026
Adage Capital Partners Gp, L.L.C.465K6.6%US$4.2MSep 30, 2026
Frazier Life Sciences Management, L.P.423K6.0%US$3.82MSep 30, 2026
Vanguard230K3.3%US$2.08MSep 30, 2026
Stonepine Capital Management, LLC189K2.7%US$1.71MSep 30, 2026
Sio Capital Management, LLC152K2.2%US$1.38MSep 30, 2026
Merck & Co., Inc.106K1.5%US$959KSep 30, 2026
Renaissance Technologies63,5530.90%US$575KSep 30, 2026
Morgan Stanley53,6740.76%US$486KSep 30, 2026
All 27 holders
HolderSharesOf the companyValueAs of
Geode Capital41,4490.59%US$375KSep 30, 2026
Two Sigma40,1040.57%US$363KSep 30, 2026
Bridgeway Capital Management, LLC17,5440.25%US$159KSep 30, 2026
Gsa Capital Partners LLP16,6730.24%US$151KSep 30, 2026
State Street13,3110.19%US$120KSep 30, 2026
Prudential Financial Inc13,1800.19%US$119KSep 30, 2026
Hrt Financial LP12,4530.18%US$112KSep 30, 2026
Northern Trust11,6500.16%US$105KSep 30, 2026
Citadel11,0610.16%US$100KSep 30, 2026
BlackRock10,9080.15%US$98,718Sep 30, 2026
Steward Partners Investment Advisory, LLC7140.01%US$6,462Sep 30, 2026
UBS544<0.01%US$4,924Sep 30, 2026
RBC98<0.01%US$1,000Sep 30, 2026
Tower Research Capital LLC (TRC)94<0.01%US$851Sep 30, 2026
Key Financial Inc59<0.01%US$534Sep 30, 2026
Jones Financial Companies Lllp58<0.01%US$524Sep 30, 2026
Citigroup Inc1<0.01%US$9Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund142K2.0%US$1.36MJun 30, 2026
Vanguard Extended Market Index Fund35,6060.50%US$341KJun 30, 2026
Fidelity Extended Market Index Fund19,8240.28%US$168KMay 31, 2026
Ultra-Small Company Fund17,5440.25%US$168KJun 30, 2026
iShares Micro-Cap ETF8,2190.12%US$78,738Jun 30, 2026
Fidelity Series Total Market Index Fund7,4760.11%US$63,247May 31, 2026
Fidelity Total Market Index Fund4,5140.06%US$38,188May 31, 2026
Fidelity Nasdaq Composite Index Fund2,7680.04%US$23,417May 31, 2026
U.S. Vector Equity Portfolio1,5070.02%US$13,729Jul 31, 2026
Dimensional US Core Equity 1 ETF1,1160.02%US$10,167Jul 31, 2026
All 13 holders
HolderSharesOf the companyValueAs of
1290 VT Micro Cap Portfolio538<0.01%US$5,154Jun 30, 2026
Vanguard Balanced Index Fund471<0.01%US$4,512Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF254<0.01%US$2,314Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Logos Global Management LP9.99%730KJun 5, 2025Schedule 13G
Coastlands Capital LP9.99%732KSep 30, 2026Schedule 13G
BCLS II Equity Opportunities, LP9.99%664KMar 31, 2026Schedule 13G
Stempoint Capital LP9.50%629KJun 30, 2026Schedule 13G
ADAR1 Capital Management, LLC9.30%381KSep 30, 2025Schedule 13G
Adage Capital Management, L.P.7.06%465KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cheryl R. Blanchard
Other companies: Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Anika Therapeutics Inc. (Director · Since at least Aug 31, 2018); Dare Bioscience, Inc. (Director · Nov 20, 2019 – Jun 21, 2023 · Past); Neuronetics, Inc. (Director · Feb 13, 2019 – May 26, 2020 · Past); SeaSpine Holdings Corp (Director · Jul 1, 2015 – May 30, 2018 · Past); Zimmer Biomet Holdings, Inc. (Sr. VP, Chief Scientific Off. · Feb 17, 2011 – Mar 19, 2012 · Past)
Board Member · Since at least Apr 15, 2026
James Shannon
Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); MannKind Corporation (Chairman of the Board · Since at least Jun 10, 2010); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past); Endocyte Inc (Director · Feb 4, 2011 – May 26, 2011 · Past)
Board Member · Since at least Jun 13, 2024
Aoife Brennan
Other companies: Climb Bio, Inc. (President and CEO, Director · Since at least Jun 27, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past); Synlogic Inc (President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past)
Director · Since at least Jun 13, 2024
Martin H Huber Jr
Other companies: Actuate Therapeutics, Inc. (Director · Since at least May 1, 2026); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 15, 2021); Mersana Therapeutics Inc (President, CEO, Director · Since at least Jan 15, 2021)
PRESIDENT AND HEAD OF R&D · Oct 21, 2021 – Aug 16, 2023 · Past
Sara Bonstein
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022); Insmed Incorporated (Chief Financial Officer · Since at least May 11, 2022)
Chair of the Board · Since at least Jun 15, 2022
Christina Rossi
Other companies: CG Oncology, Inc. (Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025); Blueprint Medicines Corp (Chief Operating Officer · Since at least Oct 29, 2018)
Director · Since at least Oct 21, 2021
Daniel J. Curran
Other companies: ALX Oncology Holdings Inc. (Director · Since at least Aug 12, 2025); Catalyst Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2025)
Board Member · Since at least Oct 21, 2021
Rachel Humphrey
Other companies: Pyxis Oncology, Inc. (Director · Since at least Aug 11, 2022); Black Diamond Therapeutics, Inc. (Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past)
Director · Oct 21, 2021 – Oct 21, 2021 · Past
René Russo
Other companies: Invivyd, Inc. (Director · Aug 5, 2021 – Aug 5, 2021 · Past); X4 Pharmaceuticals, Inc. (Director · Jun 17, 2019 – Jun 2, 2021 · Past)
President and Chief Executive Officer · Since at least Oct 21, 2021
Robert Ross
Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026)
Board Member · Since at least Jun 14, 2024
All 21 people
PersonSeat
Akintunde BelloBoard Member · Since at least Jun 10, 2025
Ben HarshbargerChief Legal Officer · Since at least Jun 29, 2026
Caroline HensleyChief Legal Officer · Dec 16, 2024 – Nov 4, 2026 · Past
Chris FrankenfieldChief Financial and Operating Officer · Since at least Nov 4, 2026
ContactScott YoungVice President, Investor Relations and Corporate Communications · Feb 12, 2025 – Nov 4, 2026 · Past
Katarina LuptakovaCHIEF MEDICAL OFFICER · Since at least Sep 5, 2023
Nathan McBrideChief Information Officer · Since at least Nov 4, 2026
Scott ColemanChief Development Officer · Since at least Nov 4, 2026
Uli BialuchaChief Scientific Officer · Since at least Apr 17, 2026
Yariv J. HouvrasChief Medical Officer · Since at least Sep 28, 2026
Yuan XuBoard Member · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Xilio Therapeutics, Inc.